Condition
Malignant Neoplastic Disease
Total Trials
5
Recruiting
0
Active
2
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
33% success
Data Visualizations
Phase Distribution
5Total
P 1 (5)
Trial Status
Terminated2
Active Not Recruiting2
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03785249Phase 1Active Not Recruiting
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT05375994Phase 1Active Not Recruiting
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
NCT05840510Phase 1Terminated
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
NCT04330664Phase 1Completed
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
NCT04975256Phase 1Terminated
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Showing all 5 trials